Long-term outcomes of isatuximab in high-risk multiple myeloma

SUMMARY

Patients with high-risk multiple myeloma (HRMM) represent a subgroup of 15–20% of MM patients and have reduced survival rates.^1,2 The current classification of HRMM includes the presence of at least one mutation associated with poor prognosis, such as del(17p), t(4;14), or t(14;16), and was extended to include 1q21+ in the second revision of the Revised International Staging System.^3,4 In recent years, new diagnostic and prognostic factors have emerged, making the HRMM disease profile even more complex.^5,6 As the prevalence of MM continues to increase globally, and the disease is still incurable, extensive research is being conducted to improve current treatment strategies.⁷ One potential improvement is the addition of anti-CD38 antibodies, such as isatuximab or daratumumab, to existing treatment regimens. At EHA 2023, Prof. Dr. Thierry Facon (Lille University Hospital, France) presented the long-term results of isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) in patients with 1q21+ status.⁸ Prof. Dr. Philippe Moreau (University Hospital of Nantes, France) discussed the results of Isa-Kd and isatuximab in combination with pomalidomide-dexamethasone (Isa-Pd) in MM patients with an ultra-high-risk profile.⁹ In addition, new data demonstrated that isatuximab with weekly Kd can be used as an appropriate and more convenient salvage regimen in patients with relapsed and/or refractory multiple myeloma (RRMM).¹⁰